FDA Clears GSK’s Requip XL For Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Once-daily version is designed to battle generic competitors.
You may also be interested in...
Generic Requip Cleared For RLS
Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.
Requip XL User Fee Date Pushed Back To Second Quarter
FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.
GSK Plans Next-Generation Restless Legs Treatment Filing In Q3 2008
U.K. drug maker also is planning to initiate a Phase III program evaluating GSK 1838262 for migraine prophylaxis.